Chiusura precedente | 0,2500 |
Aperto | 0,2500 |
Denaro | 0,0000 |
Domanda | 4,6000 |
Prezzo d'esercizio | 2,50 |
Scadenza | 2024-07-19 |
Min-Max giorno | 0,2500 - 0,2500 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 2 |
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California. Below is the list of accepted abstracts, with links to each: Sunday, November 12, 2023 Poster Presentation | Presented by Doruk E
SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which takes place September 26-28, 2023, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen’s President and Chief Executive Officer and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in a panel discussion on Tuesday, September
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. Second Quarter Highlights: Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022.Recognized total revenue of $14.1 million for the second quarter, a 26% increase over the first quarter of 2023.Achieved gross margin of 54% in the six months ended J